Practice-friendly
  • Quick turnaround time (5-7 business days)
  • Accurate diagnosis facilitates reimbursement for therapy
  • Low QNS rate
  • Concise biomarker testing lowers cost
CancerTYPE ID® has broad payment coverage
  • CancerTYPE ID is a covered benefit for Medicare Part B patients. Medicare covers 100% of the cost for Cancer TYPE ID with no copayment.
  • CancerTYPE ID testing is reimbursed by many commercial insurance companies.
  • Biotheranostics accepts formal assignment of benefits and submits insurance claims on behalf of insured patients within the United States and offers a generous patient assistance program.

Ordering Instructions

Pathology

  1. Complete all fields on Test Requisition Form.
  2. Submit the completed Test Requisition Form along with pathology report, patient insurance card(s), and specimen.
  3. Ship to Biothernostics via FedEx Priority Overnight.

Oncology

  1. Check the “Specimen Retrieval Option” box on the Test Requisition Form if you would like Biotheranostics to request the specimen from Pathology.
  2. Complete all Fields on the Test Requisition Form.
  3. Fax the form to (800) 266-9607. Biotheranostics will coordinate shipment of the patient’s sample directly from the hospital to our laboratory for testing.

Specimen Requirements

For more information, you may also contact Biotheranostics at (877) 886-6739. For specific billing information, contact Biothernostics' Reimbursement Department at (855) 682-9279.

CancerType ID Indications for Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by bioTheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.